NewsPress Releases

LifeSensors Invited to Speak at the Industry’s Preeminent 20th Annual Discovery on Target Conference

By August 30, 2022 October 11th, 2022 No Comments

LifeSensors Invited to Speak at the Industry’s Preeminent 20th Annual Discovery on Target Conference

MALVERN, Pa., AUG 30, 2022 — LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTAC, molecular glue drug discovery and neurodegeneration diagnostics has been invited to speak at Discovery on Target 2022. Dr. Karteek Kadimisetty, LifeSensors’ Director of Research and Development will be presenting new information, and answering questions regarding PROTACs, Molecular Glues, and the future of Drug Discovery from the 17th of October to the 19th in Boston Massachusetts.

Many companies make mistakes of using traditional methods to discover PROTAC or molecular glues and scientists are unable to discover novel ligands by following old methods. LifeSensors has established a new platform to discover unique PROTAC and molecular glues, molecules with the potential to deliver breakthrough drugs. The challenges and new developments in the field of ligand mediated ubiquitination will be discussed.

The LifeSensors Research and Development team will be presenting through their exhibition booth at Discovery on Target from October 17th to October 19nd in Boston to facilitate one-on-one meetings to improve your ligand discovery programs.

Discovery on Target 2022 can be followed through a variety of social media resources including Twitter using #BostonDOT22 Facebook, Linked In, or YouTube through the Cambridge Healthtech Institute.

About LifeSensors, Inc.

LifeSensors, Inc. partners with pharma and biotech companies to help life scientists innovate in basic research, drug discovery and diagnostics. We pioneered the SUMO-fusion system to measure high quality protein expression. Our development of cutting-edge tools for the ubiquitin proteasome system (UPS) and Protein Targeting Chimeras (PROTAC) gives scientists new tools to observe and test the fundamentals of this emerging area in medicine. Poly-ubiquitin affinity matrices, Tandem Ubiquitin Binding Entities (TUBES), are changing the way scientists make discoveries in UPS and how they identify new biomarkers for neurodegeneration and drug discovery.

We are making an impact in the lives of scientists through innovation and pushing the envelope with regards to novel research techniques not only in PROTAC technology, but in the growing and highly applicable areas of Molecular Glues and other technologies regarding the ubiquitin proteasome system.

Contact: Isabelle Wentzel
Business Development
LifeSensors, Inc.
(610) 644-8845 EXT. 304

Leave a Reply